CVRx director awarded stock and options

CVRx, Inc. director Martha Shadan reported equity awards that increase her stake in the company.

Rhea-AI Filing Summary

CVRx, Inc. director Martha Shadan reported equity awards that increase her stake in the company. She received 8,720 shares of Common Stock as a stock grant at no cost, bringing her direct Common Stock holdings to 8,720 shares.

She was also granted stock options for 11,182 shares of Common Stock at an exercise price of $5.43 per share, expiring on June 1, 2036. According to the footnote, these options vest on the earlier of June 1, 2027 or the company’s 2027 annual meeting of stockholders. These compensation-related awards are not open-market purchases or sales.

Insider Trade Summary

Grant/Award: 19,902 shares

Grant/Award 2 txns

Insider SHADAN MARTHA

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	11,182	$0.00	$0.00
Grant/Award	Common Stock	8,720	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 11,182 contracts (Direct); Common Stock — 8,720 shares (Direct)

Footnotes (1)

1. F1. Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders.

Key Figures

Common Stock grant: 8,720 shares Common shares held after grant: 8,720 shares Stock options granted: 11,182 options +4 more

7 metrics

Common Stock grant 8,720 shares Shares of Common Stock awarded at $0.00 per share

Common shares held after grant 8,720 shares Direct Common Stock holdings following the transaction

Stock options granted 11,182 options Stock Option (right to buy) for 11,182 underlying shares

Option exercise price $5.43 per share Conversion or exercise price of new stock options

Options held after grant 11,182 options Total reported options following the acquisition

Option expiration date June 1, 2036 Expiration date of the stock options

Option vesting trigger Earlier of June 1, 2027 or 2027 annual meeting Vesting condition from footnote F1

Key Terms

Stock Option (right to buy), exercise price, expiration date, vests, +1 more

5 terms

Stock Option (right to buy) financial

"Stock Option (right to buy) with 11,182 underlying Common Stock shares"

exercise price financial

"conversion or exercise price of $5.4300 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration date of 2036-06-01 for the stock options"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vests financial

"Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting"

annual meeting of stockholders financial

"the Issuer's 2027 annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CVRX director Martha Shadan report in this Form 4 filing?

Martha Shadan reported receiving equity awards from CVRx, Inc., including 8,720 shares of Common Stock and options for 11,182 shares. These are compensation-related grants, not open-market stock purchases or sales.

How many CVRX common shares did Martha Shadan receive in this grant?

She received 8,720 shares of Common Stock as a direct stock grant at a price of $0.00 per share. After this award, her reported direct Common Stock holdings total 8,720 shares.

What are the key terms of Martha Shadan’s new CVRX stock options?

She was granted stock options for 11,182 shares of Common Stock with an exercise price of $5.43 per share. The options expire on June 1, 2036, giving a long-term window to exercise them.

When do Martha Shadan’s new CVRX stock options vest?

The options vest on the earlier of June 1, 2027 or CVRx, Inc.’s 2027 annual meeting of stockholders. This ties vesting both to a specific date and the company’s regular governance calendar.

Is Martha Shadan’s Form 4 transaction a market purchase or sale of CVRX stock?

No, the filing shows grant and award acquisitions, not market trades. The Common Stock and options were awarded as compensation, with a transaction price of $0.00 per share, rather than bought or sold on the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 06:04 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SHADAN MARTHA

(Last) (First) (Middle)

9201 WEST BROADWAY AVE

SUITE 650

(Street)

MINNEAPOLIS MINNESOTA 55445

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CVRx, Inc. [ CVRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		A		8,720(1)	A	$0	8,720	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.43	06/01/2026		A		11,182		(1)	06/01/2036	Common Stock	11,182	$0	11,182	D

Explanation of Responses:

1. Vests on the earlier of June 1, 2027 or the Issuer's 2027 annual meeting of stockholders.

	/s/ Amy C. Seidel, Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)